Alpha Tau Medical Ltd. DRTS
14.03 USD +0.49 (+3.62%)
At closeNov 4, 2026, 7:54 PM EST
14.05 +0.02 +0.14%
After hours · Nov 4, 7:54 PM ET
13.59 Day range 14.20
3.43 52-week range 15.79
- YTD
- +183.43%
- 1 year
- +262.53%
- Market cap
- 1.30B
- EPS (ttm)
- -1.08
- Shares out
- 92.48M
- Forward P/E
- -26.24
- YTD return
- +183.43%
- 1-year return
- +262.53%
- Volume
- 685.87K
- Avg volume
- 532.37K
- Open
- 13.85
- Previous close
- 13.54
- Day's range
- 13.59 – 14.20
- 52-week range
- 3.43 – 15.79
- Beta
- 1.29
- Analysts
- Buy
- Price target
- 17.80 (+26.9%)
- Earnings date
- Nov 19, 2026
YTD +9.20 (+190.48%)
Key statistics
- Enterprise value
- 1.16B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 29.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -20.26M
- Total cash
- 100.64M
- Total debt
- 15.15M
- Return on equity
- -141.68%
- Short % of float
- 5.35%
- 50-day average
- 14.19
- 200-day average
- 10.66
Analyst view
Consensus: buy
Buy
Price target (mean) 17.80 +26.9% upside
Now 14.03
- Target (low)
- 8.00
- Target (mean)
- 17.80
- Target (high)
- 30.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 19, 2026
Expected Nov 19, 2026. Consensus EPS estimate -0.14672.
Financials — quick view
DRTS Revenue — quarterly 0
DRTS Net income — quarterly -45.81M
DRTS EPS — quarterly -0.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2026 | Sep 30, 2026 | -0.14 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.14088 | -0.50 | -0.36 | -254.91% |
| May 18, 2026 | Mar 31, 2026 | -0.13 | -0.26 | -0.13 | -100.00% |
| Mar 9, 2026 | Dec 31, 2025 | -0.13 | -0.14 | -0.01 | -7.69% |
| Nov 20, 2025 | Sep 30, 2025 | -0.12 | -0.14 | -0.02 | -16.67% |
| Aug 11, 2025 | Jun 30, 2025 | -0.12 | -0.13 | -0.01 | -8.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2026 | Barclays | main | Overweight | Overweight |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 22, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 16, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- alphatau.com
News
Alpha Tau Medical To Join TASE’s TA-90 and TA-125 Indices On November 5, 2026 
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange 
Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients 
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea 
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target 
Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study 
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting 
Alpha Tau to Participate in October Investor Conferences 
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More 
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
Your note
Sign in to keep a note on DRTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LEVY RAPHI | Chief Financial Officer | Sale | Aug 20, 2026 | 90,180 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gem Investment Advisors, LLC | 2.07% | 1,434,476 | 20.13M | Jun 29, 2026 |
| HighTower Advisors, LLC | 1.26% | 874,994 | 12.28M | Jun 29, 2026 |
| Boothbay Fund Management, LLC | 1.12% | 773,481 | 10.85M | Jun 29, 2026 |
| Aquamarine Financial (cayman) Ltd | 1.04% | 721,501 | 10.12M | Jun 29, 2026 |
| Pier Capital, LLC | 1.00% | 691,939 | 9.71M | Jun 29, 2026 |
| UBS Group AG | 0.93% | 642,263 | 9.01M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core MSCI EAFE ETF | 0.68% | 470,946 | 6.61M | Sep 29, 2026 |
| iShares Trust-iShares MSCI EAFE Small-Cap ETF | 0.31% | 217,272 | 3.05M | Sep 29, 2026 |
| ARK ETF Trust-ARK Israel Innovative Technology ETF | 0.27% | 184,377 | 2.59M | Sep 29, 2026 |
| RBB Fund, Inc.-Adara Smaller Companies Fund | 0.19% | 134,468 | 1.89M | Sep 29, 2026 |
| iShares, Inc.-iShares MSCI Israel ETF | 0.19% | 133,302 | 1.87M | Sep 29, 2026 |
| Dunham Funds-Dunham Small Cap Growth Fund | 0.10% | 71,660 | 1.01M | Jul 30, 2026 |